These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33941060)

  • 21.
    de With M; Brufau G; van den Berg LA; de Man FM; Trajkovic M; Thijs MF; Castel R; Vermeer HJ; El Bouazzaoui S; van Hemel A; Matic M; Mathijssen RHJ; Bins S; van Schaik RHN
    JCO Precis Oncol; 2022 Jul; 6():e2200180. PubMed ID: 35862869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients.
    Riera P; Riba M; Bernal S; Virgili AC; Páez D; Moreno ME
    Farm Hosp; 2021 Dec; 45(7):5-10. PubMed ID: 35379107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diversity of oncopharmacogenetic profile within Spanish population.
    Ferrer Bolufer I; Galiana Vallés X; Izquierdo Álvarez S; Serrano Mira A; Guzmán Luján C; Safont Aguilera MJ; González Tarancón R; Bolaños Naranjo M; Carrasco Salas P; Santamaría González M; Rodríguez-López R
    Pharmacogenet Genomics; 2024 Jul; 34(5):166-169. PubMed ID: 38488402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
    Kleinjan JP; Brinkman I; Bakema R; van Zanden JJ; van Rooijen JM
    Anticancer Drugs; 2019 Apr; 30(4):410-415. PubMed ID: 30628914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
    Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
    Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (
    Soria-Chacartegui P; Villapalos-García G; López-Fernández LA; Navares-Gómez M; Mejía-Abril G; Abad-Santos F; Zubiaur P
    Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
    Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
    Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Wigle TJ; Medwid S; Ross C; Schwarz UI; Kim RB
    Curr Oncol; 2023 Jan; 30(1):663-672. PubMed ID: 36661700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction.
    Medwid S; Wigle TJ; Ross C; Kim RB
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population.
    Botton MR; Hentschke-Lopes M; Matte U
    Ann Hum Genet; 2022 Mar; 86(2):102-107. PubMed ID: 34897655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
    Terrazzino S; Cargnin S; Del Re M; Danesi R; Canonico PL; Genazzani AA
    Pharmacogenomics; 2013 Aug; 14(11):1255-72. PubMed ID: 23930673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
    Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
    J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
    Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population.
    Salmani M; Ghaderi B; Fotoohi A; Omid-Shafa'at R; Vahabzadeh Z; Fotouhi O; Abdi M
    Cancer Chemother Pharmacol; 2022 Nov; 90(5):389-397. PubMed ID: 36083300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
    Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
    Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
    Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
    Jolivet C; Nassabein R; Soulières D; Weng X; Amireault C; Ayoub JP; Beauregard P; Blais N; Carrier C; Cloutier AS; Desnoyers A; Lemay AS; Lemay F; Loungnarath R; Jolivet J; Letendre F; Tehfé M; Vadnais C; Viens D; Aubin F
    Oncologist; 2021 Apr; 26(4):e597-e602. PubMed ID: 33274825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.
    Wong BYL; Li Z; Raphael MJ; De Angelis C; Hwang DM; Fu L
    J Appl Lab Med; 2024 Mar; 9(2):295-304. PubMed ID: 38084968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.